CYRAMZA
Total Payments
$15.2M
Transactions
31,945
Doctors
7,235
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $238,937 | 14 | 7 |
| 2023 | $313,664 | 85 | 76 |
| 2022 | $405,551 | 3,989 | 2,291 |
| 2021 | $2.1M | 4,266 | 2,038 |
| 2020 | $995,539 | 2,027 | 1,118 |
| 2019 | $2.1M | 4,721 | 1,914 |
| 2018 | $3.2M | 10,156 | 3,398 |
| 2017 | $5.9M | 6,687 | 2,833 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12.8M | 637 | 84.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.2M | 897 | 8.2% |
| Food and Beverage | $514,602 | 28,902 | 3.4% |
| Consulting Fee | $453,413 | 300 | 3.0% |
| Travel and Lodging | $102,958 | 666 | 0.7% |
| Education | $48,884 | 543 | 0.3% |
Payments by Type
Research
$12.8M
637 transactions
General
$2.4M
31,308 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF ERLOTINIB IN COMBINATION WITH RAMUCIRUMAB OR PLACEBO IN PREVIOUSLY UNTREATED PATIENTS WITH EGFR MUTATION-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER | Eli Lilly and Company | $1.4M | 20 |
| AN OPEN-LABEL, MULTICENTER, PHASE 1 STUDY OF RAMUCIRUMAB PLUS PEMBROLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED AND UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, NON-SMALL CELL LUNG CANCER, OR TRANSITIONAL CELL CARCINOMA OF THE UROTHELIUM, OR BILIARY TRACT CANCER | Eli Lilly and Company | $1.3M | 6 |
| A SINGLE-DOSE STUDY IN HEALTHY PARTICIPANTS TO CHARACTERIZE RAMUCIRUMAB PHARMACOKINETICS AND INVESTIGATE INJECTION SITE REACTIONS FOLLOWING AN INTRAVENOUS INFUSION OR SUBCUTANEOUS ADMINISTRATION OF RAMUCIRUMAB | Eli Lilly and Company | $1.1M | 0 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RAMUCIRUMAB PLUS DOCETAXEL VERSUS PLACEBO PLUS DOCETAXEL IN PATIENTS WITH LOCALLY ADVANCED OR UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA WHO PROGRESSED ON OR AFTER PLATINUM-BASED THERAPY | Eli Lilly and Company | $874,887 | 14 |
| A PHASE 1 STUDY OF RAMUCIRUMAB, A HUMAN MONOCLONAL ANTIBODY AGAINST THE VASCULAR ENDOTHELIAL GROWTH FACTOR-2 -VEGFR-2- RECEPTOR IN CHILDREN WITH REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS | Eli Lilly and Company | $781,361 | 3 |
| RANDOM PH II FOLFIRI+RAM/FOLFIRI+PLACEBO IN PANCREATIC CANCER | Lilly USA, LLC | $750,045 | 0 |
| A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDY OF CAPECITABINE AND CISPLATIN WITH OR WITHOUT RAMUCIRUMAB AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA-RAINFALL | Eli Lilly and Company | $740,213 | 19 |
| RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF RAMUCIRUMAB AND BEST SUPPORTIVE CARE -BSC- VERSUS PLACEBO AND BSC AS SECOND-LINE TREATMENT IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AND ELEVATED BASELINE ALPHA-FETOPROTEIN -AFP- FOLLOWING FIRST LINE THERAPY WITH SORAFENIB | Eli Lilly and Company | $664,697 | 4 |
| PHASE II STUDY OF NIVOLUMAB AND RAMUCIRUMAB FOR PATIENTS WITH PREVIOUSLY TREATED MESOTHELIOMA | Lilly USA, LLC | $638,519 | 0 |
| AN OPEN-LABEL, PHASE 1A/1B STUDY OF RAMUCIRUMAB IN COMBINATION WITH OTHER TARGETED AGENTS IN ADVANCED CANCERS | Eli Lilly and Company | $578,298 | 1 |
| PHARMACODYNAMIC PROFILES OF PRASUGREL IN PATIENTS WITH ST EL | Lilly USA, LLC | $497,106 | 0 |
| PHII STUDY OF RAM IN PTS W ADV PROGRESSIVE CARCINOID TUMORS | Lilly USA, LLC | $453,496 | 1 |
| AN OPEN-LABEL, MULTICENTER, PHASE 1 STUDY WITH EXPANSION COHORTS OF RAMUCIRUMAB OR NECITUMUMAB IN COMBINATION WITH OSIMERTINIB IN PATIENTS WITH ADVANCED T790M-POSITIVE EGFR-MUTANT NON-SMALL CELL LUNG CANCER AFTER PROGRESSION ON FIRST-LINE EGFR TKI THERAPY | Eli Lilly and Company | $371,993 | 1 |
| RANDOMIZED PHASE 2 TRIAL EVALUATING ALTERNATIVE RAMUCIRUMAB DOSES IN COMBINATION WITH PACLITAXEL IN SECOND-LINE METASTATIC OR LOCALLY ADVANCED, UNRESECTABLE GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA | Eli Lilly and Company | $341,727 | 2 |
| AN OPEN-LABEL, MULTICENTER, PHASE 1 STUDY OF RAMUCIRUMAB PLUS MEDI4736 IN PATIENTS WITH LOCALLY ADVANCED AND UNRESECTABLE OR METASTATIC GASTROINTESTINAL OR THORACIC MALIGNANCIES | Eli Lilly and Company | $323,106 | 4 |
| A PROSPECTIVE PHASE I AND II TRIAL OF RAMUCIRUMAB PEMBROLIZUMAB IN PATIENTS WITH RECURRENT METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA | Lilly USA, LLC | $267,906 | 0 |
| A RANDOMIZED PHASE 2 STUDY OF NIVOLUMAB PLUS RAMUCIRUMAB IN PATIENTS WITH RECURRENT ADVANCED METASTATIC NON-SMALL CELL LUNG CARCINOMA | Lilly USA, LLC | $251,911 | 0 |
| A PHASE II, SINGLE-ARM STUDY OF CARBOPLATIN, WEEKLY TAXANE, AND RAMUCIRUMAB IN ADVANCED NON-SQUAMOUS NSCLC AFTER PROGRESSIVE DISEASE ON MAINTENANCE PEMETREXED OR PEMBROLIZUMAB | Lilly USA, LLC | $234,922 | 0 |
| A PHASE 1/2 STUDY OF COMBINATION LORLATINIB AND RAMUCIRUMAB | Lilly USA, LLC | $175,248 | 1 |
| RAM NSCLC 2L CLINICAL ASSESSMENT OF MNSCLC PATIENTS WITH AGGRESSIVE DISEASE AND TREATED WITH CYRAMZA, IOS, OR SINGLE AGENT CHEMO USING EMR | Eli Lilly and Company | $170,500 | 0 |
Top Doctors Receiving Payments for CYRAMZA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Eduardo Acle | — | Miami, FL | $11.3M | 521 |
| , MD | Internal Medicine | New York, NY | $175,248 | 2 |
| , MD | Diagnostic Radiology | Middletown, NY | $146,220 | 7 |
| , M.D | Diagnostic Radiology | La Jolla, CA | $126,690 | 5 |
| , MD | Hematology & Oncology | Encino, CA | $111,440 | 298 |
| , M.D | Diagnostic Radiology | Kendall Park, NJ | $108,990 | 3 |
| , M.D | Specialist | Staten Island, NY | $105,963 | 4 |
| , MD | Internal Medicine | Boston, MA | $91,634 | 2 |
| , MD | Diagnostic Radiology | Santa Monica, CA | $89,008 | 5 |
| , MD | Medical Oncology | Jackson, MS | $86,208 | 112 |
| , M.D | Internal Medicine | Lexington, KY | $80,919 | 98 |
| , MD | Hematology | Stamford, CT | $75,650 | 122 |
| , M.D | Hematology & Oncology | Beverly Hills, CA | $74,715 | 91 |
| , M. D | Medical Oncology | Tampa, FL | $74,267 | 111 |
| , MD | Diagnostic Radiology | Tyler, TX | $73,638 | 3 |
| , M.D | Diagnostic Radiology | Kendall Park, NJ | $69,290 | 2 |
| , MD | Hematology & Oncology | Tampa, FL | $65,451 | 101 |
| , M.D | Hematology & Oncology | Orlando, FL | $64,106 | 77 |
| , MD | Medical Oncology | Houston, TX | $53,489 | 90 |
| , MD | Internal Medicine | New York, NY | $52,881 | 1 |
| , MD | Hematology & Oncology | Lagrange, GA | $51,081 | 118 |
| , MD | Diagnostic Radiology | Philadelphia, PA | $50,080 | 4 |
| , MD | Medical Oncology | Philadelphia, PA | $48,788 | 44 |
| , M.D | Medical Oncology | Greensboro, NC | $47,058 | 118 |
| , MD | Hematology & Oncology | Conroe, TX | $44,678 | 87 |
Ad
Manufacturing Companies
- Eli Lilly and Company $9.2M
- Lilly USA, LLC $5.6M
- Eli Lilly Export S.A. Puerto Rico Branch $156,729
- ImClone Systems, LLC $144,993
Product Information
- Type Drug
- Total Payments $15.2M
- Total Doctors 7,235
- Transactions 31,945
About CYRAMZA
CYRAMZA is a drug associated with $15.2M in payments to 7,235 healthcare providers, recorded across 31,945 transactions in the CMS Open Payments database. The primary manufacturer is Eli Lilly and Company.
Payment data is available from 2017 to 2024. In 2024, $238,937 was paid across 14 transactions to 7 doctors.
The most common payment nature for CYRAMZA is "Unspecified" ($12.8M, 84.5% of total).
CYRAMZA is associated with 20 research studies, including "A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF ERLOTINIB IN COMBINATION WITH RAMUCIRUMAB OR PLACEBO IN PREVIOUSLY UNTREATED PATIENTS WITH EGFR MUTATION-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER" ($1.4M).